| |
|
|
|
|
|
|
|||
|
Blood, 1 June 2007, Vol. 109, No. 11, pp. 4599-4606. Prepublished online as a Blood First Edition Paper on February 13, 2007; DOI 10.1182/blood-2006-08-039859.
PLENARY PAPER Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival1 Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; 2 Hematology Branch, National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, MD; 3 University of Würzburg, Germany; 4 University of Nebraska Medical Center, Omaha, NE; 5 British Columbia Cancer Center, Vancouver, BC, Canada; 6 Hospital Clinic, University of Barcelona, Spain; 7 Norwegian Radium Hospital, Oslo, Norway; 8 Southwest Oncology Group, San Antonio, TX A gene expression signature of tumor proliferation rate in mantle cell lymphoma (MCL) is an overriding molecular predictor of the length of survival following diagnosis. Many strongly proliferative MCL tumors have exceptionally high cyclin D1 mRNA levels and preferentially express short cyclin D1 mRNA isoforms. We demonstrate here that these short mRNAs are cyclin D1a isoforms with truncated 3'UTRs, not alternatively spliced cyclin D1b mRNA isoforms. Among 15 MCL tumors with truncated cyclin D1 mRNAs, 7 had genomic deletions in the CCND1 3'UTR region. In 3 others, CCND1 contained point mutations that created premature polyadenylation signals, giving rise to 1.5-kb mRNAs lacking most of the 3'UTR. Both types of genomic alteration created transcripts lacking mRNA destabilization elements present in the wild-type cyclin D1a mRNA. Premature polyadenylation due to a 3'UTR mutation also was present in the Z-138 MCL cell line, which expressed both truncated and full-length cyclin D1a mRNAs. In these cells, the half-life of the short cyclin D1a mRNA was much longer than that of the full-length mRNA. We conclude that alterations of CCND1 3'UTR structure can significantly increase its oncogenic effect and worsen the clinical course of MCL patients.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2007 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||